Perspective Therapeutics Inc (CATX)

$2.67 -0.03 (-1.11%)
Market Cap 198.48M
Revenue (ttm) 1.45M
Net Income (ttm) -79.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,467.59%
Debt to Equity Ratio 0.01
Volume 2,771,800
Avg Vol 1,792,200
Day's Range N/A - N/A
Shares Out 74.34M
Stochastic %K 74%
Beta 1.22
Analysts Strong Sell
Price Target $11.33

Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a bet...

Industry: Medical Devices
Sector: Healthcare
Phone: 206 676 0900
Address:
2401 Elliott Avenue, Suite 320, Seattle, United States
KoalaLion
KoalaLion Dec. 13 at 8:29 PM
$CATX $12 and that is only because trials are still ongoing in 2026 :) If this beats Sanofi its worth more :)
0 · Reply
BuffTrader
BuffTrader Dec. 13 at 3:04 PM
$CATX maybe if we all write to Santa and ask for $6+ pps?
0 · Reply
AG80Rider
AG80Rider Dec. 13 at 7:49 AM
$CATX
1 · Reply
AG80Rider
AG80Rider Dec. 12 at 11:36 PM
$CATX 908k traded after hours at 2.67$...
0 · Reply
Ace_of_Blue
Ace_of_Blue Dec. 12 at 10:29 PM
$CATX Am I... God?
0 · Reply
Ace_of_Blue
Ace_of_Blue Dec. 12 at 10:27 PM
$CATX Damn. They decided this penny stock has had it too good too long. Shorties strike again.
0 · Reply
Miura1957
Miura1957 Dec. 12 at 9:03 PM
$CATX they just couldn’t let it have another green day…
1 · Reply
jto2
jto2 Dec. 12 at 8:37 PM
$CATX https://m.youtube.com/watch?v=fTGVdBG7sKM
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Dec. 12 at 8:02 PM
$CATX
0 · Reply
KoalaLion
KoalaLion Dec. 12 at 7:25 PM
$CATX I feel word is on the street about the potential of this drug, ie trials that are happening now on the escalated dose, which we will know about mid 2026, and smart money is slowly buying daily.
1 · Reply
Latest News on CATX
Perspective Therapeutics to Participate in Upcoming December Conferences

Nov 20, 2025, 7:00 AM EST - 23 days ago

Perspective Therapeutics to Participate in Upcoming December Conferences

Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 11:11 PM EST - 4 weeks ago

Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Nov 10, 2025, 4:05 PM EST - 4 weeks ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Perspective Therapeutics to Participate in Upcoming November Conferences

Oct 31, 2025, 7:00 AM EDT - 6 weeks ago

Perspective Therapeutics to Participate in Upcoming November Conferences

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Oct 24, 2025, 7:00 AM EDT - 7 weeks ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript

Oct 20, 2025, 5:05 PM EDT - 7 weeks ago

Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Oct 20, 2025, 4:00 AM EDT - 7 weeks ago

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Sep 3, 2025, 7:00 AM EDT - 3 months ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Perspective Therapeutics to Participate in Upcoming September Conferences

Aug 26, 2025, 7:00 AM EDT - 3 months ago

Perspective Therapeutics to Participate in Upcoming September Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Aug 13, 2025, 6:45 AM EDT - 4 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Aug 2, 2025, 8:53 AM EDT - 4 months ago

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 24, 2025, 12:45 PM EDT - 5 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jul 15, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 6 months ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Jun 21, 2025, 8:00 AM EDT - 6 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 30, 2025, 5:21 PM EDT - 7 months ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 12, 2025, 4:36 PM EDT - 7 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

May 1, 2025, 7:00 AM EDT - 8 months ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 12:25 PM EDT - 8 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 17, 2025, 7:00 AM EDT - 8 months ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Apr 11, 2025, 7:00 AM EDT - 8 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 31, 2025, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 26, 2025, 4:10 PM EDT - 9 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 17, 2025, 7:00 AM EDT - 9 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Mar 13, 2025, 2:52 PM EDT - 9 months ago

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2025, 7:00 AM EST - 10 months ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 21, 2025, 7:00 AM EST - 10 months ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Feb 5, 2025, 7:00 AM EST - 11 months ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 24, 2025, 7:00 AM EST - 11 months ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Jan 6, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Dec 23, 2024, 11:13 AM EST - 1 year ago

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Dec 20, 2024, 4:16 PM EST - 1 year ago

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 27, 2024, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 21, 2024, 7:15 AM EST - 1 year ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 15, 2024, 4:08 PM EST - 1 year ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Oct 11, 2024, 12:05 PM EDT - 1 year ago

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 11, 2024, 8:30 AM EDT - 1 year ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 1 year ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Oct 2, 2024, 3:11 PM EDT - 1 year ago

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Oct 2, 2024, 12:10 PM EDT - 1 year ago

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

KoalaLion
KoalaLion Dec. 13 at 8:29 PM
$CATX $12 and that is only because trials are still ongoing in 2026 :) If this beats Sanofi its worth more :)
0 · Reply
BuffTrader
BuffTrader Dec. 13 at 3:04 PM
$CATX maybe if we all write to Santa and ask for $6+ pps?
0 · Reply
AG80Rider
AG80Rider Dec. 13 at 7:49 AM
$CATX
1 · Reply
AG80Rider
AG80Rider Dec. 12 at 11:36 PM
$CATX 908k traded after hours at 2.67$...
0 · Reply
Ace_of_Blue
Ace_of_Blue Dec. 12 at 10:29 PM
$CATX Am I... God?
0 · Reply
Ace_of_Blue
Ace_of_Blue Dec. 12 at 10:27 PM
$CATX Damn. They decided this penny stock has had it too good too long. Shorties strike again.
0 · Reply
Miura1957
Miura1957 Dec. 12 at 9:03 PM
$CATX they just couldn’t let it have another green day…
1 · Reply
jto2
jto2 Dec. 12 at 8:37 PM
$CATX https://m.youtube.com/watch?v=fTGVdBG7sKM
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Dec. 12 at 8:02 PM
$CATX
0 · Reply
KoalaLion
KoalaLion Dec. 12 at 7:25 PM
$CATX I feel word is on the street about the potential of this drug, ie trials that are happening now on the escalated dose, which we will know about mid 2026, and smart money is slowly buying daily.
1 · Reply
markbass2341
markbass2341 Dec. 12 at 4:05 PM
$CATX what’s going on ? mmm Let’s see rent is due and we’re trying to keep the lights on
0 · Reply
ltcman
ltcman Dec. 12 at 2:58 PM
$CATX what’s going on?
0 · Reply
Ren_Stimpy
Ren_Stimpy Dec. 12 at 12:15 PM
$CATX
0 · Reply
markbass2341
markbass2341 Dec. 12 at 2:07 AM
$CATX will be interesting Friday
0 · Reply
morty104
morty104 Dec. 11 at 10:00 PM
$CATX #pissedtil12
0 · Reply
KoalaLion
KoalaLion Dec. 11 at 8:28 PM
$CATX now that fidelity sold out someone is slowly scooping every day little by little and it is for sure not us retail folk
3 · Reply
Kingtan
Kingtan Dec. 11 at 8:07 PM
$CATX nice rebound but show me 5-6$ baby
0 · Reply
Alacrity2
Alacrity2 Dec. 11 at 6:57 PM
$CATX I am not going to lie… I am happy the way our week is going!
2 · Reply
Ace_of_Blue
Ace_of_Blue Dec. 11 at 3:27 PM
$CATX The golden calf that never stops giving, it seems.
1 · Reply
Ace_of_Blue
Ace_of_Blue Dec. 11 at 2:15 PM
$CATX She's holding steady.
0 · Reply
morty104
morty104 Dec. 11 at 1:38 PM
$GLW now that’s a chart, $CATX thank God for GLW…
0 · Reply
morty104
morty104 Dec. 11 at 1:35 PM
$CATX red headed step-chile…..
0 · Reply